Rekvina Laboratories Ltd

Healthcare · Pharmaceuticals & Biotechnology

BSE: 526075
₹48.89
▲ 0.95 (1.98%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
22/100
Weak
Valuation
—/100
Data unavailable
Momentum
51/100
Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹54 Cr
PE (TTM)
Data unavailable.
Price to Book
-44.2
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
986.4
Free Cash Flow
₹-1 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-42.86%
as of March 31, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-101.78%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
5275.00%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-245.71%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-27.27%
as of March 31, 2018
Industry median 14.05% (173 companies)
Current Ratio
0.49
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
-1.20
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-341.50
as of Sept. 30, 2025
Industry median 10.58 (182 companies)
Net Margin
-18.09%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-18.09%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-17.62%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-21.45%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
20.76%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
20.76%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (-1.20)
  • Yes Return on equity is 15% or more (20.8%)
  • No Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 4 met
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • Yes Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
2.0%
Low 48.0100 · High 48.8900
1W return
-5.9%
Low 47.9400 · High 50.9100
1M return
-1.7%
Low 47.9400 · High 59.4000
52W return
986.4%
Low 27.8300 · High 59.4000
Lifetime High ₹155.1500 (Aug. 14, 2013)
Lifetime Low ₹3.6000 (June 21, 2021)

Full price history and technicals →

EMA & SMA

Bullish3
Bearish3
5D
49.6
10D
51.0
20D
50.5
50D
40.3
100D
28.5
200D
13.3

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

48.60
Pivot
First resistance49.18
Second resistance49.48
Third resistance50.06
First support48.30
Second support47.72
Third support47.42
Day RSI51.6
Day MFI43.4
Day MACD2.47
Day MACD signal4.60

Beta

1M-0.07
3M0.06
1Y0.06
3Y0.06

Price change analysis

↓ -1.7%
Over 1 Month
LowHigh
47.9459.40
↑ 986.4%
Over 3 Months
LowHigh
27.8359.40
↑ 986.4%
Over 6 Months
LowHigh
27.8359.40
↑ 986.4%
Over 1 Year
LowHigh
27.8359.40
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹1 Cr
Net profit (June 30, 2026)
₹-0 Cr
Basic EPS (June 30, 2026)
₹-0.2000

Ranks #149 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter41.30%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 41.30% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
20 Feb 2026 PRIYANKA JAIN Bulk Buy 36,012 23.6300 BSE
26 Jun 2018 MUKESH JAMNADAS SHAH Bulk Buy 34,593 5.2300 BSE
26 Jun 2018 SURBHIT MUKESH SHAH Bulk Buy 90,207 5.2200 BSE
26 Jun 2018 ARCADIA SHARE & STOCK BROKERS PVT. LTD Bulk Sell 139,607 5.2200 BSE
25 Jun 2018 AMIT MUKESH SHAH Bulk Buy 75,000 5.2500 BSE
25 Jun 2018 MUKESH JAMNADAS SHAH Bulk Buy 75,000 5.2500 BSE
25 Jun 2018 ARCADIA SHARE & STOCK BROKERS PVT. LTD Bulk Sell 150,000 5.2500 BSE
11 Apr 2017 G N CREDITS PRIVATE LIMITED Bulk Sell 34,560 5.1000 BSE
11 Apr 2017 MUKESH JAMNADAS SHAH Bulk Buy 56,000 5.1000 BSE
11 Apr 2017 SOBHANAND Bulk Sell 56,500 5.1000 BSE

All bulk and block deals →

Corporate Announcements

All 3 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 AGM/EGM Rekvina Laboratories Ltd - 526075 - Shareholder Meeting / Postal Ballot-Outcome of AGM
29 Sep 2026 AGM/EGM Rekvina Laboratories Ltd - 526075 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
12 Sep 2026 Company Update Rekvina Laboratories Ltd - 526075 - Announcement under Regulation 30 (LODR)-Resignation of Chairman and Managing Director

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

  • Thin net profit margin (-18.1%)
  • Negative shareholder equity (Debt/Equity -1.20) -- accumulated losses exceed paid-in capital
  • Tight liquidity (Current Ratio 0.49)
  • Declining revenue YoY (-27.3%)
  • Declining profit YoY (-245.7%)

Opportunities

Data unavailable.

Threats

  • Weak interest coverage (-341.5x) -- limited cushion against rising rates

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Rekvina Laboratories Ltd

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.